$RGPX
REGENEREX PHARMA, INC. Stock $rgpx

$rgpx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000147237524000045 Filed on June 24, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2024
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development			$2.400M
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.144K		$4.278K
YoY Change	37.67%		25.09%
% of Gross Profit
Operating Expenses	$254.3K		$3.466M
YoY Change	58.75%		3503.82%
Operating Profit	-$254.3K		-$3.466M
YoY Change	58.75%		3503.82%
Interest Expense	$22.33K		$80.64K
YoY Change	20.68%		20.74%
% of Operating Profit
Other Income/Expense, Net	-$18.28K		-$78.00K
YoY Change	-28.03%		89.51%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$272.6K		-$3.544M
YoY Change	46.87%		2480.52%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	278.2M shares	278.0M shares	277.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$372.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$2.357K	$2.540K
Receivables
Other Receivables
Total Short-Term Assets	$2.357K	$2.912K
YoY Change	-97.41%	156.56%
LONG-TERM ASSETS
Property, Plant & Equipment		$6.097K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$726.7K	$763.8K
YoY Change	-23.38%	14033.38%
TOTAL ASSETS
Total Short-Term Assets	$2.357K	$2.912K
Total Long-Term Assets	$726.7K	$763.8K
Total Assets	$729.1K	$766.7K
YoY Change	-29.87%	11624.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$160.7K	$116.8K
YoY Change	66.52%	55.38%
Accrued Expenses	$107.0K	$97.25K
YoY Change	38.97%	-22.69%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.414M	$3.843M
YoY Change	450.5%	394.78%
LONG-TERM LIABILITIES
Long-Term Debt		$184.2K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$184.2K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.414M	$3.843M
Total Long-Term Liabilities	$0.00	$184.2K
Total Liabilities	$5.042M	$4.829M
YoY Change	137.45%	327.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.888M	-$5.616M
YoY Change	160.83%	171.03%
Common Stock	$278.3K	$278.2K
YoY Change	0.33%	0.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.313M	-$4.062M
YoY Change
Total Liabilities & Shareholders Equity	$729.1K	$766.7K
YoY Change	-29.87%	11624.73%

Cashflow Statement

Concept	2024 Q2	2024
OPERATING ACTIVITIES
Net Income	-$272.6K	-$3.544M
YoY Change	46.87%	2480.52%
Depreciation, Depletion And Amortization	$1.144K	$4.278K
YoY Change	37.67%	25.09%
Cash From Operating Activities	-$55.33K	-$457.5K
YoY Change	-54.36%	500.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$6.299K
YoY Change		350.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$54.96K	$463.1K
YoY Change	-71.3%	508.86%
NET CHANGE
Cash From Operating Activities	-$55.33K	-$457.5K
Cash From Investing Activities		-$6.299K
Cash From Financing Activities	$54.96K	$463.1K
Net Change In Cash	-$372.00	-$763.00
YoY Change	-100.56%	-49.3%
FREE CASH FLOW
Cash From Operating Activities	-$55.33K	-$457.5K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	RGPX	Operating Leases Rou Asset And Liabilities OperatingLeasesRouAssetAndLiabilities		usd
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001357878
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2024Q1	RGPX	Notes Payable Related Parties NotesPayableRelatedParties		usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
CY2023	RGPX	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation		usd
CY2023	us-gaap	Proceeds From Repayments Of Other Debt ProceedsFromRepaymentsOfOtherDebt		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2024	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2024	us-gaap	Interest Paid InterestPaid		usd
CY2023	us-gaap	Interest Paid InterestPaid		usd
CY2023	RGPX	Accrued Interest Converted Into Note Payable AccruedInterestConvertedIntoNotePayable		usd
CY2023	RGPX	Noncash Or Part Noncash Acquisition Of Intangible Assets Excluding Goodwill NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill		usd
CY2024Q1	RGPX	Accrued Administration Expenses AccruedAdministrationExpenses		usd
CY2023Q1	RGPX	Accrued Asset Purchase Agreement Liability AccruedAssetPurchaseAgreementLiability		usd
CY2024Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2024	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value per share
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Public Float EntityPublicFloat	0	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	278225910	shares
CY2024	dei	Auditor Firm AuditorFirmId	3501
CY2024	dei	Auditor Name AuditorName	dbbmckennon
CY2024	dei	Auditor Location AuditorLocation	Newport Beach, California
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	372	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1135	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2540	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	2912	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	1135	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	29272	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	26397	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1328	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4203	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1600	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	197	usd
CY2024Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	6097	usd
CY2023Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1201	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	756343	usd
CY2024Q1	us-gaap	Assets Assets	766680	usd
CY2023Q1	us-gaap	Assets Assets	6539	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	116760	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	75145	usd
CY2024Q1	RGPX	Related Party Advances RelatedPartyAdvances	3690	usd
CY2023Q1	RGPX	Related Party Advances RelatedPartyAdvances	131887	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	511847	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	221192	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	97251	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	125787	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	2400000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	128264	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3843362	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	776782	usd
CY2024Q1	us-gaap	Notes Payable NotesPayable	119114	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	314704	usd
CY2023Q1	RGPX	Notes Payable Related Parties NotesPayableRelatedParties	38000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	184232	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	681798	usd
CY2024Q1	us-gaap	Liabilities Liabilities	4828506	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1129486	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	675000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	675000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	278225910	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	278225910	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	277112660	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	277112660	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	278226	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	277113	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1275798	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	671963	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5615850	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2072023	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-4061826	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1122947	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	766680	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6539	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1065825	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	96171	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2400000	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	3465825	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	96171	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-3465825	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-96171	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2636	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	25629	usd
CY2024	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-78002	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-41159	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-3543827	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-137330	usd
CY2024	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.01
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.00
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	277653029	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	277112660	shares
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-3543827	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-137330	usd
CY2024	us-gaap	Depreciation Depreciation	4278	usd
CY2023	us-gaap	Depreciation Depreciation	3420	usd
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2636	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	25629	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	211698	usd
CY2024	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2400000	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	53719	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2540	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	5256	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	159641	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	43999	usd
CY2024	RGPX	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	290655	usd
CY2024	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-28536	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	34120	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-457548	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76164	usd
CY2024	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	6299	usd
CY2023	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	1398	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6299	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1398	usd
CY2024	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	3490	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	200	usd
CY2024	us-gaap	Proceeds From Repayments Of Other Debt ProceedsFromRepaymentsOfOtherDebt	-10000	usd
CY2024	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-47500	usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-2500	usd
CY2024	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	393250	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	463084	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76057	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-763	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1505	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1135	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2640	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	372	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1135	usd
CY2024	RGPX	Accrued Interest Converted Into Note Payable To Shareholder AccruedInterestConvertedIntoNotePayableToShareholder	66469	usd
CY2023	RGPX	Accrued Interest Converted Into Note Payable To Shareholder AccruedInterestConvertedIntoNotePayableToShareholder	30294	usd
CY2024	RGPX	Accrued Interest Converted Into Note Payable AccruedInterestConvertedIntoNotePayable	52545	usd
CY2024	RGPX	Operating Leases Rou Asset And Liabilities OperatingLeasesRouAssetAndLiabilities	953355	usd
CY2024	RGPX	Noncash Or Part Noncash Acquisition Of Intangible Assets Excluding Goodwill NoncashOrPartNoncashAcquisitionOfIntangibleAssetsExcludingGoodwill	2400000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-137330	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1122947	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1122947	usd
CY2024	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	393250	shares
CY2024	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	720000	shares
CY2024	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	211698	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-3543827	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-4061826	usd
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; font-size: 10pt"><b>NOTE 1 – NATURE OF OPERATIONS</b></p> <p style="margin-top: 0px; margin-bottom: 0px; font-size: 10pt"> </p> <p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: justify; font-size: 10pt">Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on November 18, 2005.</p> <p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: justify; font-size: 10pt">On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15<sup>th</sup> of the following month, for a period of 60 months. On August 17, 2023, the Company entered into an Agreement to Purchase Technology Platforms in which the Company purchased certain intellectual property in exchange for an interest-free two million four hundred thousand dollars ($2,400,000) note payable that is due August 17, 2024. The note payable is due within twelve (12) months of the date of the agreement. If the Company has not raised a minimum of ten million dollars ($10,000,000) in sales within twelve (12) months, or a minimum of ten million dollars ($10,000,000) in investment, the seller will extend the payments for a further period of twelve (12) months for a 10% payment of the outstanding balance.</p> <p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Risks and Uncertainties</i></p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows.</p> <p style="margin: 0px; font-size: 10pt"> </p> <p style="margin: 0px; text-align: justify; font-size: 10pt">The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p>
CY2024	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2005-11-18
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	10000000	usd
CY2024Q1	RGPX	Current Liabilities In Excess Of Current Assets CurrentLiabilitiesInExcessOfCurrentAssets	3840450	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin: 0px; text-align: justify; font-size: 10pt"><i>Basis of Presentation and Use of Estimates</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">These financial statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could ultimately differ from those estimates.</p> <p style="margin: 0px; text-align: justify; font-size: 10pt"> </p>
CY2024Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	29847	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	9192	usd
CY2024Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P3Y
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2875	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3223	usd
CY2024	us-gaap	Property Plant And Equipment Preproduction Design And Development Costs PropertyPlantAndEquipmentPreproductionDesignAndDevelopmentCosts	<p style="margin: 0px; text-align: justify; font-size: 10pt"><i style="font-size: 10pt">Furniture and Computer Equipment</i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt"><i> </i></p> <p style="margin: 0px; text-align: justify; font-size: 10pt">Furniture and computer equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of three (3) to five (5) years. Depreciation expense for the years ended March 31, 2024 and 2023 was $1,403 and $197, respectively. Significant betterments are capitalized while purchases under $500 are expensed as incurred.</p> <p style="margin: 0px; font-size: 10pt"> </p>
CY2024	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1403	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	197	usd
CY2024Q1	us-gaap	Lessee Finance Lease Discount Rate LesseeFinanceLeaseDiscountRate	0.10	pure
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	482000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	212000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	511847	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	221192	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	12375	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	4800	usd
CY2023Q1	RGPX	Accrued Administration Expenses AccruedAdministrationExpenses	9744	usd
CY2024Q1	RGPX	Accrued Asset Purchase Agreement Liability AccruedAssetPurchaseAgreementLiability	15488	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	69388	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	111243	usd
CY2024Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	97251	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	125787	usd
CY2024	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.10	pure
CY2024	us-gaap	Repayments Of Debt RepaymentsOfDebt	47500	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	2500	usd
CY2024	us-gaap	Interest Expense Debt InterestExpenseDebt	4934	usd
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	1725	usd
CY2021Q4	us-gaap	Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued	150000000	shares
CY2021Q4	us-gaap	Business Combination Contingent Consideration Arrangements Description BusinessCombinationContingentConsiderationArrangementsDescription	and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months.
CY2025Q1	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	475050	usd
CY2026Q1	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	119114	usd
CY2024Q1	us-gaap	Accounts Payable Interest Bearing Current And Noncurrent AccountsPayableInterestBearingCurrentAndNoncurrent	58504	usd
CY2023Q1	us-gaap	Accounts Payable Interest Bearing Current And Noncurrent AccountsPayableInterestBearingCurrentAndNoncurrent	51892	usd
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	18150	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	usd
CY2024	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On June 10, 2023, the Company entered into a plant facility lease agreement with a related party commencing June 9, 2023 which expires on June 30, 2028. Under this agreement, the monthly rental payments are $18,000 throughout the term of the lease excepting the month of June 2023 the rent is $7,920. To commence with production, the plant needs to prepare for FDA inspection which will include inspection of the facility, equipment, and the Company’s procedures. We expect to launch production during the Company’s second quarter of our fiscal year ending March 31, 2025, and will notify the FDA to come into the plant for the inspection at that time. The Company is able to start production while the plant waits for the FDA Inspection. Until the certification is complete, and the Company is in production, the monthly rent is reduced by forty (40%) percent to $10,800. Under this agreement, the Company is also leasing the equipment in the plant facility through five (5) annual rent payments of $10,000, which are due on the 15th day of each June from June 2023 to June 2027.
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	675000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2608250	shares
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	2578214	shares
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.013	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0000	pure
CY2024	RGPX	Effective Income Tax Rate Reconciliation Accounts Payable And Accrued Liabilities EffectiveIncomeTaxRateReconciliationAccountsPayableAndAccruedLiabilities	-0.001	pure
CY2023	RGPX	Effective Income Tax Rate Reconciliation Accounts Payable And Accrued Liabilities EffectiveIncomeTaxRateReconciliationAccountsPayableAndAccruedLiabilities	0.071	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.155	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.068	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.041	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.213	pure
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2024Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	581500	usd
CY2023Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	14300	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	464100	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	345800	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1045500	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	360100	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	685400	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	29200	usd
CY2024Q1	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	2200000	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	10000000	usd

Files In Submission

Name	View Source	Status
0001472375-24-000045-index-headers.html	Edgar Link	pending
0001472375-24-000045-index.html	Edgar Link	pending
0001472375-24-000045.txt	Edgar Link	pending
0001472375-24-000045-xbrl.zip	Edgar Link	pending
exhibit31-1.htm	Edgar Link	pending
exhibit31-2.htm	Edgar Link	pending
exhibit32-1.htm	Edgar Link	pending
exhibit32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ixform10k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
ixform10k_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regenerexlogo.gif	Edgar Link	pending
report.css	Edgar Link	pending
rgpx-20240331.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
rgpx-20240331_cal.xml	Edgar Link	unprocessable
rgpx-20240331_lab.xml	Edgar Link	unprocessable
rgpx-20240331_def.xml	Edgar Link	unprocessable
rgpx-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGPX
REGENEREX PHARMA, INC. Stock $rgpx

2024 Q2 Form 10-K Financial Statement

#000147237524000045 Filed on June 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGPX REGENEREX PHARMA, INC. Stock $rgpx

2024 Q2 Form 10-K Financial Statement

#000147237524000045 Filed on June 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGPX
REGENEREX PHARMA, INC. Stock $rgpx